154607-00-8

Usage

Uses

Used in Pharmaceutical Industry:
2-Bromo-5-hydroxybenzoic acid Methyl ester is used as a key intermediate in the synthesis of macrocyclic Mcl-1 inhibitors. These inhibitors are designed for the treatment of multiple myeloma, a type of blood cancer. The compound plays a crucial role in the development of novel therapeutic agents that target the Mcl-1 protein, which is overexpressed in multiple myeloma cells and contributes to the resistance of these cells to apoptosis.
In the pharmaceutical industry, 2-Bromo-5-hydroxybenzoic acid Methyl ester is used as a building block for the creation of macrocyclic Mcl-1 inhibitors. These inhibitors are specifically designed to target and inhibit the Mcl-1 protein, which is overexpressed in multiple myeloma cells and plays a significant role in the resistance of these cells to apoptosis. By inhibiting Mcl-1, these macrocyclic compounds can potentially enhance the effectiveness of current treatments for multiple myeloma and improve patient outcomes.

Upstream product

• 19438-10-9 methyl 3-hydroxybenzoate 
• 67-56-1 methanol 
• 58380-11-3 2-bromo-5-hydroxybenzoic acid 
• 22921-68-2 2-bromo-5-methoxy-benzoic acid 
• 35450-36-3 methyl 2-bromo-5-methoxybenzoate 

Downstream Products

• 705279-03-4 methyl 2-bromo-5-(difluoromethoxy)benzenecarboxylate 
• 765944-34-1 5-ethoxy-2-bromo-benzoic acid methyl ester 
• 1147012-19-8 methyl 2-bromo-5-[2-(methylsulfonyl)phenoxy]benzoate 
• 1171823-98-5 methyl 2-bromo-5-(4-fluorobenzyloxy)benzoate 
• 1392119-23-1 5-benzyloxy-2-(3-hydroxyprop-1-ynyl)benzoic acid methyl ester 
• 1392119-24-2 5-benzyloxy-2-[3-(tert-butyldimethylsilanyloxy)prop-1-ynyl]benzoic acid methyl ester 
• 1392119-25-3 7-benzyloxy-4-bromo-3-(tert-butyldimethylsilanyloxymethyl)isochromen-1-one 
• 1392119-26-4 7-benzyloxy-3-(tert-butyldimethylsilanyloxymethyl)-4-(5-methylchroman-6-yl)isochromen-1-one 
• 1392119-28-6 7-benzyloxy-3-hydroxymethyl-2-methyl-4-(5-methylchroman-6-yl)-2H-isoquinolin-1-one 
• 1392119-30-0 7-benzyloxy-2-methyl-4-(5-methylchroman-6-yl)-1-oxo-1,2-dihydroisoquinoline-3-carbaldehyde 
• 1392119-32-2 [7-benzyloxy-2-methyl-4-(5-methylchroman-6-yl)-1-oxo-1,2-dihydroisoquinolin-3-yl]trimethylsilanyloxyacetonitrile 
• 879369-15-0 2-bromo-5-(2-fluoroethoxy)benzoic acid 

Relevant academic research and scientific papers

A Chan-Evans-Lam approach to trisubstituted vinyl ethers

Trisubstituted vinyl ethers were accessedviaChan-Evans-Lam coupling of vinyl trifluoroborates and primary aliphatic alcohols. This approach complements prior methods that required the use of neat liquid alcohol coupling partners. A palladium-catalyzed redox-relay Heck reaction was used to convert several vinyl ethers into aldehyde-functionalized 1,3-dihydroisobenzofurans.

Synthesis of a triethylene glycol-capped benzo[1,2-c:4,5-c']bis[2]benzopyran-5,12-dione: A highly soluble dilactone-bridged p-terphenyl with a crankshaft architecture

3,10-Bis(triethylene glycol)benzo[1,2-c:4,5-c']bis[2]benzopyran-5,12-dione has been synthesized as an example of a dilactone-bridged p-terphenyl with a C2h crankshaft architecture that exhibits significant fluorescence. Lactone-bridged rotation

Near infrared fluorescent probe capable of being used for responding to pH change in living cells in chronic wound development process and preparation method of probe

The invention discloses a near infrared fluorescent probe capable of being used for responding to the pH change in living cells in the chronic wound development process and a preparation method of theprobe, and belongs to the technical field of biological

A pH-sensitive near-infrared fluorescent probe with alkaline p: K a for chronic wound monitoring in diabetic mice

A pH-sensitive near-infrared fluorescent probe with alkaline pKa, AlkaP-1, was developed by incorporating a benzoyl hydrazine group into a cyanine dye. The significant fluorescence changes in the alkaline regions enable the probe to monitor the alkalization process from acute wounds to chronic wounds in diabetic mice.

Concise Synthesis of a Potential 5-Lipoxygenase Activating Protein (FLAP) Inhibitor and Its Analogs through Late-Stage Alkene Dicarbofunctionalization

We report a five-step synthesis of the biologically important 1,1-diarylalkane 1, a potential 5-lipoxygenase activating protein (FLAP) inhibitor that was synthesized previously in 12 steps. In this synthesis, we apply a three-component alkene dicarbofunct

Structure-Based Approach to Identify 5-[4-Hydroxyphenyl]pyrrole-2-carbonitrile Derivatives as Potent and Tissue Selective Androgen Receptor Modulators

In an effort to find new and safer treatments for osteoporosis and frailty, we describe a novel series of selective androgen receptor modulators (SARMs). Using a structure-based approach, we identified compound 7, a potent AR (ARE EC50 = 0.34 nM) and selective (N/C interaction EC50 = 1206 nM) modulator. In vivo data, an AR LBD X-ray structure of 7, and further insights from modeling studies of ligand receptor interactions are also presented.

Ruthenium-Catalyzed Hydroarylation and One-Pot Twofold Unsymmetrical C?H Functionalization of Arenes

A methyl phenyl sulfoximine (MPS) is used as a directing group in the ruthenium-catalyzed intramolecular hydroarylation of alkene-tethered benzoic acid derivatives to afford dihydrobenzofurans and indolines in good to excellent yields. A one-pot, unsymmetrical, twofold C?H functionalization involving intramolecular C?C and intermolecular C?C/C?N bond formations is successfully demonstrated by using a single set of catalytic reaction conditions, which is unprecedented thus far. A novel isoquinolone-bearing dihydrobenzofuran is constructed through an unsymmetrical twofold C?H functionalization.

NOVEL CHARTREUSIN ANALOGUES

The present invention relates to novel Chartreusin analogues of formula (I), pharmaceutical compositions comprising the same and to their use for the treatment of cancer and other diseases.

Synthetic remodeling of the chartreusin pathway to tune antiproliferative and antibacterial activities

Natural products of the benzonaphthopyranone class, such as chartreusin, elsamicin A, gilvocarcin, and polycarcin, represent potent leads for urgently needed anticancer therapeutics and antibiotics. Since synthetic protocols for altering their architectur

ISOQUINOLINE COMPOUNDS AND METHODS FOR TREATING HIV

Provided are compounds and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and their use for treating viral infections mediated by a member of the retrovirus family of viruses such as the Human Immunodeficiency Virus (HIV).